Outlook Therapeutics (OTLK) Capital Leases (2015 - 2022)
Outlook Therapeutics (OTLK) reported Capital Leases of $1084.0 for Q4 2022, down 91.8% year-over-year from $13221.0 in Q4 2021, and down 74.6% quarter-over-quarter from $4267.0 in Q3 2022.
Outlook Therapeutics (OTLK) Capital Leases (2015 - 2022) Analysis & Trends
Outlook Therapeutics (OTLK) has 8 years of Capital Leases data on file, last reported at $1084.0 in Q4 2022.
- Capital Leases for Q4 2022 came in at $1084.0, down 91.8% year-over-year; the trailing twelve-month figure through Dec 2022 was $1084.0 (down 91.8% YoY), and the FY2022 annual result was $4267.0, down 73.36% from the prior year.
- Capital Leases eased to $1084.0 in Q4 2022 per OTLK's latest filing, from $4267.0 in the prior quarter.
- Over five years, Capital Leases peaked at $3.5 million in Q1 2018 and troughed at $1084.0 in Q4 2022.
- A 5-year average of $1.5 million and a median of $45822.0 in 2020 frame the typical range for Capital Leases.
- The sharpest annual moves came in 2018 and 2021: Capital Leases surged 12203.62% in 2018, then slumped 99.14% in 2021.
- A 5-year view of Capital Leases shows it stood at $3.4 million in 2018, then fell by 1.64% to $3.3 million in 2019, then tumbled by 98.93% to $35682.0 in 2020, then tumbled by 62.95% to $13221.0 in 2021, then sank by 91.8% to $1084.0 in 2022.
- Business Quant data shows OTLK's Capital Leases at $1084.0 in Q4 2022, $4267.0 in Q3 2022, and $7349.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1,084.00 |
| Sep 30, 2022 | 4,267.00 |
| Jun 30, 2022 | 7,349.00 |
| Mar 31, 2022 | 10,332.00 |
| Dec 31, 2021 | 13,221.00 |
| Sep 30, 2021 | 16,018.00 |
| Jun 30, 2021 | 21,703.00 |
| Mar 31, 2021 | 28,755.00 |
| Dec 31, 2020 | 35,682.00 |
| Sep 30, 2020 | 42,482.00 |
| Jun 30, 2020 | 49,162.00 |
| Mar 31, 2020 | 3.35 Mn |
| Dec 31, 2019 | 3.34 Mn |
| Sep 30, 2019 | 3.37 Mn |
| Jun 30, 2019 | 3.35 Mn |
| Mar 31, 2019 | 3.39 Mn |
| Dec 31, 2018 | 3.40 Mn |
| Sep 30, 2018 | 3.45 Mn |
| Jun 30, 2018 | 3.51 Mn |
| Mar 31, 2018 | 3.51 Mn |